Our Reports
Automotive ReportsElectronics & SemiconductorTelecom & ITTechnology & ITConsumer GoodsHealthcareFood & BeveragesChemical
Our Links
About UsContact UsPress ReleaseNewsOur Blogs

Int'l : +1(646) 600-5072 | query@kbvresearch.com

Global Myasthenia Gravis Treatment Market Size, Share & Industry Trends Analysis Report By End-use (Hospitals, Clinics and Others), By Type, By Regional Outlook and Forecast, 2023 - 2030

Published Date : 30-Nov-2023

Pages: 216

Formats: PDF

The Global Myasthenia Gravis Treatment Market size is expected to reach $3.8 billion by 2030, rising at a market growth of 9.2% CAGR during the forecast period.

Better awareness and improved diagnostic techniques led to more cases being identified, increasing the demand for myasthenia gravis treatments, including chronic immunomodulators. Therefore, chronic immunomodulators segment captured $127.2 million revenue in the market in 2022. Research into autoimmune diseases, including myasthenia gravis, has spurred the development of newer and more effective chronic immunomodulators. Companies invest in developing improved formulations or alternative medications with better efficacy and fewer side effects. Thus, due to these factors, the segment will witness increased demand in the coming years. Some of the factors impacting the market are increased awareness and diagnosis of myasthenia gravis, growing usage and development of biological drugs and targeted therapies, and lack of treatment options for myasthenia gravis.

Myasthenia Gravis Treatment Market Size - Global Opportunities and Trends Analysis Report 2019-2030

Early diagnosis means more identified cases of myasthenia gravis. This expands the patient pool seeking treatment. As more patients are diagnosed early, there's a higher demand for treatments, medications, and therapies, potentially creating a larger opportunity for pharmaceutical companies and healthcare providers. Early intervention often means a more manageable disease course. Moreover, as more attention is drawn to the disease, regulatory bodies and funding agencies might show increased interest. This can result in expedited review processes, regulatory support, and potentially increased funding for research and development in the myasthenia gravis treatment space. Additionally, unlike more generalized immunosuppressive treatments, biologics and targeted therapies focus on specific components of the immune system responsible for the autoimmune response in myasthenia gravis. For instance, some drugs may target B cells, producing autoantibodies that attack the neuromuscular junction. Moreover, introducing biological drugs has spurred increased research and clinical trials focusing on these targeted therapies. This ongoing research contributes to an expanding knowledge base and potential for further advancements in treatment options for myasthenia gravis. These aspects will drive the expansion of the market.

However, myasthenia gravis is known for its heterogeneity, meaning the symptoms, severity, and treatment response can differ significantly among individuals. What works well for one patient might not be as effective for another. This makes it challenging to find a universally effective treatment. Many medications commonly used to manage myasthenia gravis symptoms can lead to various side effects. These factors are expected to hamper the growth of the market.

Additionally, many individuals with chronic conditions like MG faced disruptions in their routine healthcare services due to overwhelmed healthcare systems, reallocation of resources, and restrictions on non-essential services during the pandemic's peak. Restrictions on in-person consultations limited access to specialized care from neurologists and other MG specialists, impacting disease management and individualized treatment plans. The unavailability or delay in receiving prescribed medications led to interruptions in the treatment, potentially impacting the control of MG symptoms. Inadequate access to essential medications resulted in disease exacerbations or flares, leading to increased weakness, fatigue, and other symptoms associated with MG. Therefore, the COVID-19 pandemic had a negative impact on the myasthenia gravis treatment market.

Type Outlook

On the basis of type, the market is segmented into cholinesterase inhibitors, chronic immunomodulators, monoclonal antibodies, rapid immunotherapies, thymectomy, and others. The monoclonal antibodies segment recorded the maximum revenue share in the market in 2022. Monoclonal antibodies are a type of biological therapy that targets certain immune system components suspected to be involved in the etiology of myasthenia gravis.

Myasthenia Gravis Treatment Market Share and Industry Analysis Report 2022

End-Use Outlook

Based on end-use, the market is divided into hospitals, clinics, and others. In 2022, the clinics segment witnessed a substantial revenue share in the market. Clinics specifically dedicated to neuromuscular disorders, including myasthenia gravis, provide comprehensive care with neurologists, immunologists, and other specialists experienced in managing this condition. The demand for specialized care could fuel the growth of such clinics.

Myasthenia Gravis Treatment Market Report Coverage
Report Attribute Details
Market size value in 2022 USD 1.9 Billion
Market size forecast in 2030 USD 3.8 Billion
Base Year 2022
Historical Period 2019 to 2021
Forecast Period 2023 to 2030
Revenue Growth Rate CAGR of 9.2% from 2023 to 2030
Number of Pages 216
Number of Table 290
Report coverage Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Porter’s 5 Forces Analysis, Company Profiling, Companies Strategic Developments, SWOT Analysis, Winning Imperatives
Segments covered Type, End-use, Region
Country scope
  • North America (US, Canada, Mexico, and Rest of North America)
  • Europe (Germany, UK, France, Russia, Spain, Italy, and Rest of Europe)
  • Asia Pacific (China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific)
  • LAMEA (Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA)
Companies Included AstraZeneca PLC (Alexion Pharmaceuticals, Inc.), Octapharma AG, Novartis AG, Pfizer, Inc., Allergan PLC (AbbVie, Inc.), F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC (GSK), Bausch Health Companies Inc., Kedrion S.p.A, and Zydus Lifesciences Ltd.
Growth Drivers
  • Increased awareness and diagnosis of myasthenia gravis
  • Growing usage and development of biological drugs and targeted therapies
Restraints
  • Lack of treatment options for myasthenia gravis

Regional Outlook

By region, the market is segmented into North America, Europe, Asia Pacific, and LAMEA. The North America segment procured the highest revenue share in the market in 2022. North America has seen a considerable prevalence of myasthenia gravis. Better diagnostic capabilities and increased awareness among healthcare professionals have led to more accurate and timely diagnoses of the condition, driving the demand for treatments.

Free Valuable Insights: Global Myasthenia Gravis Treatment Market size to reach USD 3.8 Billion by 2030

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC (Alexion Pharmaceuticals, Inc.), Octapharma AG, Novartis AG, Pfizer, Inc., Allergan PLC (AbbVie, Inc.), F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC (GSK), Bausch Health Companies Inc., Kedrion S.p.A, and Zydus Lifesciences Ltd.

Scope of the Study

Market Segments Covered in the Report:

By End-use

  • Hospitals
  • Clinics
  • Others

By Type

  • Monoclonal Antibodies
  • Thymectomy
  • Cholinesterase Inhibitors
  • Chronic Immunomodulators
  • Rapid Immunotherapies
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

  • AstraZeneca PLC (Alexion Pharmaceuticals, Inc.)
  • Octapharma AG
  • Novartis AG
  • Pfizer, Inc.
  • Allergan PLC (AbbVie, Inc.)
  • F.Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC (GSK)
  • Bausch Health Companies Inc.
  • Kedrion S.p.A
  • Zydus Lifesciences Ltd.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Myasthenia Gravis Treatment Market, by End-use
1.4.2 Global Myasthenia Gravis Treatment Market, by Type
1.4.3 Global Myasthenia Gravis Treatment Market, by Geography
1.5 Methodology for the research

Chapter 2. Market at a Glance
2.1 Key Highlights

Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter Five Forces Analysis

Chapter 4. Global Myasthenia Gravis Treatment Market by End-use
4.1 Global Hospitals Market by Region
4.2 Global Clinics Market by Region
4.3 Global Others Market by Region

Chapter 5. Global Myasthenia Gravis Treatment Market by Type
5.1 Global Monoclonal Antibodies Market by Region
5.2 Global Thymectomy Market by Region
5.3 Global Cholinesterase Inhibitors Market by Region
5.4 Global Chronic Immunomodulators Market by Region
5.5 Global Rapid Immunotherapies Market by Region
5.6 Global Others Market by Region

Chapter 6. Global Myasthenia Gravis Treatment Market by Region
6.1 North America Myasthenia Gravis Treatment Market
6.1.1 North America Myasthenia Gravis Treatment Market by End-use
6.1.1.1 North America Hospitals Market by Country
6.1.1.2 North America Clinics Market by Country
6.1.1.3 North America Others Market by Country
6.1.2 North America Myasthenia Gravis Treatment Market by Type
6.1.2.1 North America Monoclonal Antibodies Market by Country
6.1.2.2 North America Thymectomy Market by Country
6.1.2.3 North America Cholinesterase Inhibitors Market by Country
6.1.2.4 North America Chronic Immunomodulators Market by Country
6.1.2.5 North America Rapid Immunotherapies Market by Country
6.1.2.6 North America Others Market by Country
6.1.3 North America Myasthenia Gravis Treatment Market by Country
6.1.3.1 US Myasthenia Gravis Treatment Market
6.1.3.1.1 US Myasthenia Gravis Treatment Market by End-use
6.1.3.1.2 US Myasthenia Gravis Treatment Market by Type
6.1.3.2 Canada Myasthenia Gravis Treatment Market
6.1.3.2.1 Canada Myasthenia Gravis Treatment Market by End-use
6.1.3.2.2 Canada Myasthenia Gravis Treatment Market by Type
6.1.3.3 Mexico Myasthenia Gravis Treatment Market
6.1.3.3.1 Mexico Myasthenia Gravis Treatment Market by End-use
6.1.3.3.2 Mexico Myasthenia Gravis Treatment Market by Type
6.1.3.4 Rest of North America Myasthenia Gravis Treatment Market
6.1.3.4.1 Rest of North America Myasthenia Gravis Treatment Market by End-use
6.1.3.4.2 Rest of North America Myasthenia Gravis Treatment Market by Type
6.2 Europe Myasthenia Gravis Treatment Market
6.2.1 Europe Myasthenia Gravis Treatment Market by End-use
6.2.1.1 Europe Hospitals Market by Country
6.2.1.2 Europe Clinics Market by Country
6.2.1.3 Europe Others Market by Country
6.2.2 Europe Myasthenia Gravis Treatment Market by Type
6.2.2.1 Europe Monoclonal Antibodies Market by Country
6.2.2.2 Europe Thymectomy Market by Country
6.2.2.3 Europe Cholinesterase Inhibitors Market by Country
6.2.2.4 Europe Chronic Immunomodulators Market by Country
6.2.2.5 Europe Rapid Immunotherapies Market by Country
6.2.2.6 Europe Others Market by Country
6.2.3 Europe Myasthenia Gravis Treatment Market by Country
6.2.3.1 Germany Myasthenia Gravis Treatment Market
6.2.3.1.1 Germany Myasthenia Gravis Treatment Market by End-use
6.2.3.1.2 Germany Myasthenia Gravis Treatment Market by Type
6.2.3.2 UK Myasthenia Gravis Treatment Market
6.2.3.2.1 UK Myasthenia Gravis Treatment Market by End-use
6.2.3.2.2 UK Myasthenia Gravis Treatment Market by Type
6.2.3.3 France Myasthenia Gravis Treatment Market
6.2.3.3.1 France Myasthenia Gravis Treatment Market by End-use
6.2.3.3.2 France Myasthenia Gravis Treatment Market by Type
6.2.3.4 Russia Myasthenia Gravis Treatment Market
6.2.3.4.1 Russia Myasthenia Gravis Treatment Market by End-use
6.2.3.4.2 Russia Myasthenia Gravis Treatment Market by Type
6.2.3.5 Spain Myasthenia Gravis Treatment Market
6.2.3.5.1 Spain Myasthenia Gravis Treatment Market by End-use
6.2.3.5.2 Spain Myasthenia Gravis Treatment Market by Type
6.2.3.6 Italy Myasthenia Gravis Treatment Market
6.2.3.6.1 Italy Myasthenia Gravis Treatment Market by End-use
6.2.3.6.2 Italy Myasthenia Gravis Treatment Market by Type
6.2.3.7 Rest of Europe Myasthenia Gravis Treatment Market
6.2.3.7.1 Rest of Europe Myasthenia Gravis Treatment Market by End-use
6.2.3.7.2 Rest of Europe Myasthenia Gravis Treatment Market by Type
6.3 Asia Pacific Myasthenia Gravis Treatment Market
6.3.1 Asia Pacific Myasthenia Gravis Treatment Market by End-use
6.3.1.1 Asia Pacific Hospitals Market by Country
6.3.1.2 Asia Pacific Clinics Market by Country
6.3.1.3 Asia Pacific Others Market by Country
6.3.2 Asia Pacific Myasthenia Gravis Treatment Market by Type
6.3.2.1 Asia Pacific Monoclonal Antibodies Market by Country
6.3.2.2 Asia Pacific Thymectomy Market by Country
6.3.2.3 Asia Pacific Cholinesterase Inhibitors Market by Country
6.3.2.4 Asia Pacific Chronic Immunomodulators Market by Country
6.3.2.5 Asia Pacific Rapid Immunotherapies Market by Country
6.3.2.6 Asia Pacific Others Market by Country
6.3.3 Asia Pacific Myasthenia Gravis Treatment Market by Country
6.3.3.1 China Myasthenia Gravis Treatment Market
6.3.3.1.1 China Myasthenia Gravis Treatment Market by End-use
6.3.3.1.2 China Myasthenia Gravis Treatment Market by Type
6.3.3.2 Japan Myasthenia Gravis Treatment Market
6.3.3.2.1 Japan Myasthenia Gravis Treatment Market by End-use
6.3.3.2.2 Japan Myasthenia Gravis Treatment Market by Type
6.3.3.3 India Myasthenia Gravis Treatment Market
6.3.3.3.1 India Myasthenia Gravis Treatment Market by End-use
6.3.3.3.2 India Myasthenia Gravis Treatment Market by Type
6.3.3.4 South Korea Myasthenia Gravis Treatment Market
6.3.3.4.1 South Korea Myasthenia Gravis Treatment Market by End-use
6.3.3.4.2 South Korea Myasthenia Gravis Treatment Market by Type
6.3.3.5 Singapore Myasthenia Gravis Treatment Market
6.3.3.5.1 Singapore Myasthenia Gravis Treatment Market by End-use
6.3.3.5.2 Singapore Myasthenia Gravis Treatment Market by Type
6.3.3.6 Malaysia Myasthenia Gravis Treatment Market
6.3.3.6.1 Malaysia Myasthenia Gravis Treatment Market by End-use
6.3.3.6.2 Malaysia Myasthenia Gravis Treatment Market by Type
6.3.3.7 Rest of Asia Pacific Myasthenia Gravis Treatment Market
6.3.3.7.1 Rest of Asia Pacific Myasthenia Gravis Treatment Market by End-use
6.3.3.7.2 Rest of Asia Pacific Myasthenia Gravis Treatment Market by Type
6.4 LAMEA Myasthenia Gravis Treatment Market
6.4.1 LAMEA Myasthenia Gravis Treatment Market by End-use
6.4.1.1 LAMEA Hospitals Market by Country
6.4.1.2 LAMEA Clinics Market by Country
6.4.1.3 LAMEA Others Market by Country
6.4.2 LAMEA Myasthenia Gravis Treatment Market by Type
6.4.2.1 LAMEA Monoclonal Antibodies Market by Country
6.4.2.2 LAMEA Thymectomy Market by Country
6.4.2.3 LAMEA Cholinesterase Inhibitors Market by Country
6.4.2.4 LAMEA Chronic Immunomodulators Market by Country
6.4.2.5 LAMEA Rapid Immunotherapies Market by Country
6.4.2.6 LAMEA Others Market by Country
6.4.3 LAMEA Myasthenia Gravis Treatment Market by Country
6.4.3.1 Brazil Myasthenia Gravis Treatment Market
6.4.3.1.1 Brazil Myasthenia Gravis Treatment Market by End-use
6.4.3.1.2 Brazil Myasthenia Gravis Treatment Market by Type
6.4.3.2 Argentina Myasthenia Gravis Treatment Market
6.4.3.2.1 Argentina Myasthenia Gravis Treatment Market by End-use
6.4.3.2.2 Argentina Myasthenia Gravis Treatment Market by Type
6.4.3.3 UAE Myasthenia Gravis Treatment Market
6.4.3.3.1 UAE Myasthenia Gravis Treatment Market by End-use
6.4.3.3.2 UAE Myasthenia Gravis Treatment Market by Type
6.4.3.4 Saudi Arabia Myasthenia Gravis Treatment Market
6.4.3.4.1 Saudi Arabia Myasthenia Gravis Treatment Market by End-use
6.4.3.4.2 Saudi Arabia Myasthenia Gravis Treatment Market by Type
6.4.3.5 South Africa Myasthenia Gravis Treatment Market
6.4.3.5.1 South Africa Myasthenia Gravis Treatment Market by End-use
6.4.3.5.2 South Africa Myasthenia Gravis Treatment Market by Type
6.4.3.6 Nigeria Myasthenia Gravis Treatment Market
6.4.3.6.1 Nigeria Myasthenia Gravis Treatment Market by End-use
6.4.3.6.2 Nigeria Myasthenia Gravis Treatment Market by Type
6.4.3.7 Rest of LAMEA Myasthenia Gravis Treatment Market
6.4.3.7.1 Rest of LAMEA Myasthenia Gravis Treatment Market by End-use
6.4.3.7.2 Rest of LAMEA Myasthenia Gravis Treatment Market by Type

Chapter 7. Company Profiles
7.1 AstraZeneca PLC (Alexion Pharmaceuticals, Inc.)
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Approval and Trails:
7.1.6 SWOT Analysis
7.2 Octapharma AG
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Research & Development Expenses
7.3 Novartis AG
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.3.5 SWOT Analysis
7.4 Pfizer, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional & Segmental Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Approval and Trails:
7.4.6 SWOT Analysis
7.5 Allergan PLC (AbbVie, Inc.)
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.1 Research & Development Expense
7.5.2 SWOT Analysis
7.6 F. Hoffmann-La Roche Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.6.5 SWOT Analysis
7.7 GlaxoSmithKline PLC (GSK)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expense
7.7.5 SWOT Analysis
7.8 Bausch Health Companies Inc
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expenses
7.8.5 SWOT Analysis
7.9 Kedrion S.p.A
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Research & Development Expenses
7.9.4 SWOT Analysis
7.10. Zydus Lifesciences Ltd.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
7.10.5 SWOT Analysis

Chapter 8. Winning imperatives of Myasthenia Gravis Treatment Market
TABLE 1 Global Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 2 Global Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 3 Global Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 4 Global Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 5 Global Hospitals Market by Region, 2019 - 2022, USD Million
TABLE 6 Global Hospitals Market by Region, 2023 - 2030, USD Million
TABLE 7 Global Clinics Market by Region, 2019 - 2022, USD Million
TABLE 8 Global Clinics Market by Region, 2023 - 2030, USD Million
TABLE 9 Global Others Market by Region, 2019 - 2022, USD Million
TABLE 10 Global Others Market by Region, 2023 - 2030, USD Million
TABLE 11 Global Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 12 Global Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 13 Global Monoclonal Antibodies Market by Region, 2019 - 2022, USD Million
TABLE 14 Global Monoclonal Antibodies Market by Region, 2023 - 2030, USD Million
TABLE 15 Global Thymectomy Market by Region, 2019 - 2022, USD Million
TABLE 16 Global Thymectomy Market by Region, 2023 - 2030, USD Million
TABLE 17 Global Cholinesterase Inhibitors Market by Region, 2019 - 2022, USD Million
TABLE 18 Global Cholinesterase Inhibitors Market by Region, 2023 - 2030, USD Million
TABLE 19 Global Chronic Immunomodulators Market by Region, 2019 - 2022, USD Million
TABLE 20 Global Chronic Immunomodulators Market by Region, 2023 - 2030, USD Million
TABLE 21 Global Rapid Immunotherapies Market by Region, 2019 - 2022, USD Million
TABLE 22 Global Rapid Immunotherapies Market by Region, 2023 - 2030, USD Million
TABLE 23 Global Others Market by Region, 2019 - 2022, USD Million
TABLE 24 Global Others Market by Region, 2023 - 2030, USD Million
TABLE 25 Global Myasthenia Gravis Treatment Market by Region, 2019 - 2022, USD Million
TABLE 26 Global Myasthenia Gravis Treatment Market by Region, 2023 - 2030, USD Million
TABLE 27 North America Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 28 North America Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 29 North America Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 30 North America Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 31 North America Hospitals Market by Country, 2019 - 2022, USD Million
TABLE 32 North America Hospitals Market by Country, 2023 - 2030, USD Million
TABLE 33 North America Clinics Market by Country, 2019 - 2022, USD Million
TABLE 34 North America Clinics Market by Country, 2023 - 2030, USD Million
TABLE 35 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 36 North America Others Market by Country, 2023 - 2030, USD Million
TABLE 37 North America Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 38 North America Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 39 North America Monoclonal Antibodies Market by Country, 2019 - 2022, USD Million
TABLE 40 North America Monoclonal Antibodies Market by Country, 2023 - 2030, USD Million
TABLE 41 North America Thymectomy Market by Country, 2019 - 2022, USD Million
TABLE 42 North America Thymectomy Market by Country, 2023 - 2030, USD Million
TABLE 43 North America Cholinesterase Inhibitors Market by Country, 2019 - 2022, USD Million
TABLE 44 North America Cholinesterase Inhibitors Market by Country, 2023 - 2030, USD Million
TABLE 45 North America Chronic Immunomodulators Market by Country, 2019 - 2022, USD Million
TABLE 46 North America Chronic Immunomodulators Market by Country, 2023 - 2030, USD Million
TABLE 47 North America Rapid Immunotherapies Market by Country, 2019 - 2022, USD Million
TABLE 48 North America Rapid Immunotherapies Market by Country, 2023 - 2030, USD Million
TABLE 49 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 50 North America Others Market by Country, 2023 - 2030, USD Million
TABLE 51 North America Myasthenia Gravis Treatment Market by Country, 2019 - 2022, USD Million
TABLE 52 North America Myasthenia Gravis Treatment Market by Country, 2023 - 2030, USD Million
TABLE 53 US Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 54 US Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 55 US Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 56 US Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 57 US Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 58 US Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 59 Canada Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 60 Canada Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 61 Canada Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 62 Canada Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 63 Canada Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 64 Canada Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 65 Mexico Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 66 Mexico Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 67 Mexico Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 68 Mexico Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 69 Mexico Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 70 Mexico Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 71 Rest of North America Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 72 Rest of North America Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 73 Rest of North America Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 74 Rest of North America Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 75 Rest of North America Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 76 Rest of North America Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 77 Europe Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 78 Europe Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 79 Europe Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 80 Europe Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 81 Europe Hospitals Market by Country, 2019 - 2022, USD Million
TABLE 82 Europe Hospitals Market by Country, 2023 - 2030, USD Million
TABLE 83 Europe Clinics Market by Country, 2019 - 2022, USD Million
TABLE 84 Europe Clinics Market by Country, 2023 - 2030, USD Million
TABLE 85 Europe Others Market by Country, 2019 - 2022, USD Million
TABLE 86 Europe Others Market by Country, 2023 - 2030, USD Million
TABLE 87 Europe Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 88 Europe Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 89 Europe Monoclonal Antibodies Market by Country, 2019 - 2022, USD Million
TABLE 90 Europe Monoclonal Antibodies Market by Country, 2023 - 2030, USD Million
TABLE 91 Europe Thymectomy Market by Country, 2019 - 2022, USD Million
TABLE 92 Europe Thymectomy Market by Country, 2023 - 2030, USD Million
TABLE 93 Europe Cholinesterase Inhibitors Market by Country, 2019 - 2022, USD Million
TABLE 94 Europe Cholinesterase Inhibitors Market by Country, 2023 - 2030, USD Million
TABLE 95 Europe Chronic Immunomodulators Market by Country, 2019 - 2022, USD Million
TABLE 96 Europe Chronic Immunomodulators Market by Country, 2023 - 2030, USD Million
TABLE 97 Europe Rapid Immunotherapies Market by Country, 2019 - 2022, USD Million
TABLE 98 Europe Rapid Immunotherapies Market by Country, 2023 - 2030, USD Million
TABLE 99 Europe Others Market by Country, 2019 - 2022, USD Million
TABLE 100 Europe Others Market by Country, 2023 - 2030, USD Million
TABLE 101 Europe Myasthenia Gravis Treatment Market by Country, 2019 - 2022, USD Million
TABLE 102 Europe Myasthenia Gravis Treatment Market by Country, 2023 - 2030, USD Million
TABLE 103 Germany Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 104 Germany Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 105 Germany Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 106 Germany Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 107 Germany Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 108 Germany Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 109 UK Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 110 UK Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 111 UK Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 112 UK Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 113 UK Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 114 UK Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 115 France Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 116 France Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 117 France Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 118 France Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 119 France Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 120 France Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 121 Russia Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 122 Russia Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 123 Russia Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 124 Russia Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 125 Russia Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 126 Russia Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 127 Spain Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 128 Spain Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 129 Spain Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 130 Spain Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 131 Spain Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 132 Spain Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 133 Italy Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 134 Italy Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 135 Italy Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 136 Italy Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 137 Italy Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 138 Italy Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 139 Rest of Europe Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 140 Rest of Europe Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 141 Rest of Europe Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 142 Rest of Europe Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 143 Rest of Europe Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 144 Rest of Europe Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 145 Asia Pacific Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 146 Asia Pacific Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 147 Asia Pacific Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 148 Asia Pacific Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 149 Asia Pacific Hospitals Market by Country, 2019 - 2022, USD Million
TABLE 150 Asia Pacific Hospitals Market by Country, 2023 - 2030, USD Million
TABLE 151 Asia Pacific Clinics Market by Country, 2019 - 2022, USD Million
TABLE 152 Asia Pacific Clinics Market by Country, 2023 - 2030, USD Million
TABLE 153 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
TABLE 154 Asia Pacific Others Market by Country, 2023 - 2030, USD Million
TABLE 155 Asia Pacific Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 156 Asia Pacific Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 157 Asia Pacific Monoclonal Antibodies Market by Country, 2019 - 2022, USD Million
TABLE 158 Asia Pacific Monoclonal Antibodies Market by Country, 2023 - 2030, USD Million
TABLE 159 Asia Pacific Thymectomy Market by Country, 2019 - 2022, USD Million
TABLE 160 Asia Pacific Thymectomy Market by Country, 2023 - 2030, USD Million
TABLE 161 Asia Pacific Cholinesterase Inhibitors Market by Country, 2019 - 2022, USD Million
TABLE 162 Asia Pacific Cholinesterase Inhibitors Market by Country, 2023 - 2030, USD Million
TABLE 163 Asia Pacific Chronic Immunomodulators Market by Country, 2019 - 2022, USD Million
TABLE 164 Asia Pacific Chronic Immunomodulators Market by Country, 2023 - 2030, USD Million
TABLE 165 Asia Pacific Rapid Immunotherapies Market by Country, 2019 - 2022, USD Million
TABLE 166 Asia Pacific Rapid Immunotherapies Market by Country, 2023 - 2030, USD Million
TABLE 167 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
TABLE 168 Asia Pacific Others Market by Country, 2023 - 2030, USD Million
TABLE 169 Asia Pacific Myasthenia Gravis Treatment Market by Country, 2019 - 2022, USD Million
TABLE 170 Asia Pacific Myasthenia Gravis Treatment Market by Country, 2023 - 2030, USD Million
TABLE 171 China Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 172 China Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 173 China Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 174 China Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 175 China Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 176 China Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 177 Japan Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 178 Japan Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 179 Japan Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 180 Japan Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 181 Japan Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 182 Japan Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 183 India Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 184 India Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 185 India Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 186 India Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 187 India Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 188 India Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 189 South Korea Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 190 South Korea Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 191 South Korea Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 192 South Korea Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 193 South Korea Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 194 South Korea Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 195 Singapore Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 196 Singapore Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 197 Singapore Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 198 Singapore Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 199 Singapore Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 200 Singapore Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 201 Malaysia Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 202 Malaysia Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 203 Malaysia Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 204 Malaysia Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 205 Malaysia Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 206 Malaysia Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 207 Rest of Asia Pacific Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 208 Rest of Asia Pacific Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 209 Rest of Asia Pacific Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 210 Rest of Asia Pacific Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 211 Rest of Asia Pacific Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 212 Rest of Asia Pacific Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 213 LAMEA Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 214 LAMEA Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 215 LAMEA Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 216 LAMEA Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 217 LAMEA Hospitals Market by Country, 2019 - 2022, USD Million
TABLE 218 LAMEA Hospitals Market by Country, 2023 - 2030, USD Million
TABLE 219 LAMEA Clinics Market by Country, 2019 - 2022, USD Million
TABLE 220 LAMEA Clinics Market by Country, 2023 - 2030, USD Million
TABLE 221 LAMEA Others Market by Country, 2019 - 2022, USD Million
TABLE 222 LAMEA Others Market by Country, 2023 - 2030, USD Million
TABLE 223 LAMEA Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 224 LAMEA Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 225 LAMEA Monoclonal Antibodies Market by Country, 2019 - 2022, USD Million
TABLE 226 LAMEA Monoclonal Antibodies Market by Country, 2023 - 2030, USD Million
TABLE 227 LAMEA Thymectomy Market by Country, 2019 - 2022, USD Million
TABLE 228 LAMEA Thymectomy Market by Country, 2023 - 2030, USD Million
TABLE 229 LAMEA Cholinesterase Inhibitors Market by Country, 2019 - 2022, USD Million
TABLE 230 LAMEA Cholinesterase Inhibitors Market by Country, 2023 - 2030, USD Million
TABLE 231 LAMEA Chronic Immunomodulators Market by Country, 2019 - 2022, USD Million
TABLE 232 LAMEA Chronic Immunomodulators Market by Country, 2023 - 2030, USD Million
TABLE 233 LAMEA Rapid Immunotherapies Market by Country, 2019 - 2022, USD Million
TABLE 234 LAMEA Rapid Immunotherapies Market by Country, 2023 - 2030, USD Million
TABLE 235 LAMEA Others Market by Country, 2019 - 2022, USD Million
TABLE 236 LAMEA Others Market by Country, 2023 - 2030, USD Million
TABLE 237 LAMEA Myasthenia Gravis Treatment Market by Country, 2019 - 2022, USD Million
TABLE 238 LAMEA Myasthenia Gravis Treatment Market by Country, 2023 - 2030, USD Million
TABLE 239 Brazil Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 240 Brazil Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 241 Brazil Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 242 Brazil Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 243 Brazil Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 244 Brazil Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 245 Argentina Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 246 Argentina Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 247 Argentina Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 248 Argentina Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 249 Argentina Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 250 Argentina Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 251 UAE Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 252 UAE Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 253 UAE Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 254 UAE Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 255 UAE Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 256 UAE Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 257 Saudi Arabia Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 258 Saudi Arabia Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 259 Saudi Arabia Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 260 Saudi Arabia Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 261 Saudi Arabia Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 262 Saudi Arabia Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 263 South Africa Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 264 South Africa Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 265 South Africa Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 266 South Africa Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 267 South Africa Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 268 South Africa Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 269 Nigeria Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 270 Nigeria Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 271 Nigeria Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 272 Nigeria Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 273 Nigeria Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 274 Nigeria Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 275 Rest of LAMEA Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 276 Rest of LAMEA Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 277 Rest of LAMEA Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 278 Rest of LAMEA Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 279 Rest of LAMEA Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 280 Rest of LAMEA Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 281 KEY INFORMATION – ASTRAZENECA PLC
TABLE 282 Key Information – Octapharma AG
TABLE 283 Key Information – Novartis AG
TABLE 284 Key Information – Pfizer, Inc.
TABLE 285 Key Information – Allergan PLC
TABLE 286 Key Information – F. Hoffmann-La Roche Ltd.
TABLE 287 Key Information – GlaxoSmithKline PLC
TABLE 288 Key Information – Bausch Health Companies Inc
TABLE 289 key Information – Kedrion S.p.A
TABLE 290 Key Information – Zydus Lifesciences Ltd.

List of Figures
FIG 1 Methodology for the research
FIG 2 Global Myasthenia Gravis Treatment Market, 2019 - 2030, USD Million
FIG 3 Key Factors Impacting Myasthenia Gravis Treatment Market
FIG 4 Porter’s Five Forces Analysis – Myasthenia Gravis Treatment Market
FIG 5 Global Myasthenia Gravis Treatment Market share by End-use, 2022
FIG 6 Global Myasthenia Gravis Treatment Market share by End-use, 2030
FIG 7 Global Myasthenia Gravis Treatment Market by End-use, 2019 - 2030, USD Million
FIG 8 Global Myasthenia Gravis Treatment Market share by Type, 2022
FIG 9 Global Myasthenia Gravis Treatment Market share by Type, 2030
FIG 10 Global Myasthenia Gravis Treatment Market by Type, 2019 - 2030, USD Million
FIG 11 Global Myasthenia Gravis Treatment Market share by Region, 2022
FIG 12 Global Myasthenia Gravis Treatment Market share by Region, 2030
FIG 13 Global Myasthenia Gravis Treatment Market by Region, 2019 - 2030, USD Million
FIG 14 SWOT Analysis: AstraZeneca PLC
FIG 15 SWOT Analysis: Novartis AG
FIG 16 SWOT Analysis: Pfizer, Inc.
FIG 17 SWOT Analysis: Allergan PLC
FIG 18 Swot Analysis: F. Hoffmann-La Roche Ltd.
FIG 19 SWOT Analysis: GlaxoSmithKline PLC
FIG 20 SWOT Analysis: Bausch Health Companies Inc
FIG 21 SWOT Analysis: Kedrion S.p.A
FIG 22 SWOT Analysis: Zydus Lifesciences Ltd.

Purchase Full Report of
Myasthenia Gravis Treatment Market

Buy Now

Avail up to 60% discount on subscription plans on

SUBSCRIPTION MODEL